IP Library › Granted Patent US 12692513
Granted Patent B2
US 12692513 · App. 17/366,545 · Granted Jul 28, 2026

Prostate neoantigens and their uses

Inventors: Jason Lee DeHart (San Diego, CA); Vipul Bhargava (Warrington, PA); Patrick Wilkinson (Collegeville, PA); Manuel Alejandro Sepulveda (West Windsor, NJ)
Assignee: Janssen Biotech, Inc.
C12N15/86A61K39/0011A61K39/001193A61K2039/5154A61K2039/53A61K2039/545A61K2039/884C12N2710/10343C12N2710/24143C12N2770/36143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692513
App. No.
17/366,545
Granted
Jul 28, 2026
Kind
B2
Abstract

Disclosed herein are self-replicating RNA molecules encoding prostate neoantigens, vaccines, and method of treating and preventing prostate cancer using the self-replicating RNA molecules and vaccines.

Claims (11)

1 . A method of treating a prostate cancer in a subject, the method comprising administering to the subject:

a) first vaccine comprising an Ad26 vector comprising a polynucleotide encoding the polypeptides of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23, and 177; and

b) a second vaccine comprising a self-replicating RNA molecule comprising a polynucleotide encoding the polypeptides of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23, and 177.

2 . The method of claim 1 , wherein the self-replicating RNA molecule is an alphavirus.

3 . The method of claim 2 , wherein the alphavirus is Eastern equine encephalitis virus (EEEV), Venezuelan equine encephalitis virus (VEEV), Everglades virus (EVEV), Mucambo virus (MUCV), Semliki forest virus (SFV), Pixuna virus (PIXV), Middelburg virus (MIDV), Chikungunya virus (CHIKV), O'Nyong-Nyong virus (ONNV), Ross River virus (RRV), Barmah Forest virus (BF), Getah virus (GET), Sagiyama virus (SAGV), Bebaru virus (BEBV), Mayaro virus (MAYV), Una virus (UNAV), Sindbis virus (SINV), Aura virus (AURAV), Whataroa virus (WHAV), Babanki virus (BABV), Kyzylagach virus (KYZV), Western equine encephalitis virus (WEEV), Highland J virus (HJV), Fort Morgan virus (FMV), Ndumu (NDUV), or Buggy Creek virus.

4 . The method of claim 3 , wherein the alphavirus is a Venezuelan equine encephalitis virus (VEEV).

5 . The method of claim 1 , wherein the prostate cancer is a relapsed prostate cancer, a refractory prostate cancer, a metastatic prostate cancer, a castration resistant prostate cancer, or any combination thereof.

6 . The method of claim 1 , comprising administering an additional cancer therapeutic agent to the subject.

7 . The method of claim 1 , wherein the first vaccine is administered one or more times to the subject.

8 . The method of claim 1 , wherein the second vaccine is administered one or more times to the subject.

9 . The method of claim 1 , wherein the first vaccine is administered about 1-16 weeks prior to administering the second vaccine.